What will the average number of measles cases be during Trump's term?

**Stage 0 — clarification / working assumption**: The market question text is ambiguous about the threshold that defines a Yes/No outcome. For a useful, testable analysis I assume *Yes = the average annual number of confirmed U.S. measles cases over 2025–2028 is >= 2,000 cases/year* (i.e., a 4‑year average >= 2,000). If the market’s threshold differs you should tell me; the quantitative logic below will easily be re-run for another cutoff.

**Stage 1 — Blind analysis (ignore market prices)**

- Current baseline facts: CDC‑sourced reporting summarized in media shows ~2,030 confirmed cases in 2026 (to date) and reporting that 2025 was also above 2,000 (RFK Jr’s 2,200 figure matches media accounts). That implies a two‑year run (2025–2026) at ~2k+ each year. Two years at ~2,200 + 2,030 = ~4,230 total.

- What the 2,000/year average threshold requires: To average >=2,000 across 4 years, total cases across 2025–2028 must be >= 8,000. With ~4,230 already in 2025–26, the sum of 2027+2028 must be >= 3,770 (an average of ~1,885 each year). That is a substantial continuation of current high incidence, though not literally identical to 2025–26 levels.

- Arguments from epidemiology and historical patterns: - Measles dynamics are driven by population susceptibility (vaccine coverage gaps and clustering), importations, and local transmission amplification. Once multiple states report sustained community transmission, the chance of additional large outbreaks in later years rises. Two consecutive years >2,000 demonstrates this is not a single anomalous importation spike. - However, measles historically shows strong year‑to‑year variability driven by outbreak extinguishment once susceptible clusters are immunized or outbreaks burn out, public awareness increases, and targeted vaccination campaigns are launched. Large declines in subsequent years are plausible. - Policy and behavioral drivers matter: federal leadership, state vaccination policies, school mandates, outbreak response resources, and misinformation trends (which appear to be elevated) all influence trajectory. The current federal administration’s public stances and appointees could either slow or accelerate vaccination uptake.

- Probabilistic synthesis (blind): Given two observed years >2,000, the probability of *continuing* levels in 2027–28 sufficient to keep the 4‑year average >=2,000 is non‑negligible but not dominant. I estimate that there is a material chance outbreaks subside (due to targeted campaigns and natural outbreak burn‑out) and a material chance they persist or worsen (due to persistent pockets of undervaccination and misinformation). Combining epidemiological priors and the observed run, my independent (blind) estimate that the 4‑year average >=2,000 is **~35%**.

**Stage 2 — Market calibration (look at current prices)**

- Current market: Yes = 0.31, No = 0.69 with substantial volume (~147k contracts). The market is pricing a ~31% probability for Yes. My blind estimate (35%) is very close to that price.

- Why the market might be at ~31% (and why that is close to my estimate): Liquidity suggests many traders have incorporated the two years >2,000 but also price in the plausibility of strong decline in 2027–28 (public health responses, natural burn‑out, seasonality). The market may also internalize unmodeled risks (improved reporting reducing undercount bias vs. reporting artifacts) and risk aversion / margin constraints that slightly compress probabilities toward the larger, status‑quo outcome (No).

- Reasons market could be slightly mispriced either way: - Downside mispricing (market too pessimistic about Yes): If vaccine hesitancy, reduced school mandates, and administrative policies materially slow outbreak control, 2027–28 could sustain or increase cases — pushing the market’s 31% too low. The market may underweight the compounding effect of transmissible clusters. - Upside mispricing (market too optimistic about Yes): If targeted interventions, surge vaccination campaigns, and restoration of strong public‑health messaging reduce susceptible clusters rapidly, 2027–28 could fall substantially below 1,885/year on average and the market’s 31% is too high.

- Conclusion on calibration: The market price (31%) is broadly consistent with my independent view (35%). I see no large arbitrage edge; the market and my independent estimate are in the same ballpark. If you are risk‑tolerant and believe recent political/policy signals will worsen coverage, there is an arguable edge to taking a Yes position; if you expect effective public‑health response, No is appropriately priced higher.